Breast Cancer  & Herceptin

FDA Expands Use of Herceptin for Early Stage Breast Cancer After Primary Therapy
In 1998, FDA approved Herceptin for the treatment of metastatic breast cancer (cancer that has spread to other sites in the body. Today's approval ...
Herceptin Improves Breast Cancer Survival - National Cancer Institute
Patients with operable breast cancer whose tumors over-expressed HER-2 were enrolled in these studies between February 2000 and April 2005.
ACS :: Early Herceptin Use a Breast Cancer Breakthrough
After about 2 years, those treated with Herceptin had a 52% lower risk of their breast cancer coming back.
Herceptin: Safe Breast Cancer Stopper
Dec. 15, 2006 (San Antonio) -- The breast cancer breast cancer drug Herceptin prevents breast cancer cancer from coming back in some women, new ...

1  2  3  |  Next »
WikipediaTrastuzumab is a humanized monoclonal antibody that acts on the HER2/neu receptor. Herceptins principal use is as an anti-cancer therapy in breast cancer in patients whose tumors overexpress this receptor. Trastuzumab is administered either once a ... Read More

Loading RightHealth Community...

RightHealth Daily Dose

One tidbit everyday from RightHealth Staff

US Reporting Largest Measles Outbreak Since 2001

The largest measles outbreak since 2001 is currently happening in ten states across the US. More than 70 people ranging from infants to the elderly are affected - most of them were never vaccinated for measles. CDC officials are currently stressing the importance of proper vaccination in children. Measles is a highly contagious disease caused by a virus. It can lead to inner ear infections, bronchitis, pneumonia, and even brain inflammation. Full story.

Your health is important. Take charge of it with RightHealth Daily Dose - sign up for the daily email!

Meet Dr. Gwenn


RightHealth's Pediatrics Expert

"Play Ball"...but play it safe and for fun!!
It's becoming a tradition. Opening Day for the Boston Red Sox arrives and I find myself posting on youth sports safety. Why? Read more.

Page last updated April 23, 2008